Adenocarcinoma of Esophagogastric Junction Clinical Trial
— NICLAOfficial title:
Efficacy and Safety of PD-1 Combined With Long-term Concurrent Neoadjuvant Chemoradiotherapy and Chemotherapy in the Treatment of Resectable Locally Advanced Esophagogastric Junction Adenocarcinoma: A Phase II Study
The purpose of this study was to evaluate the effect and safety of concurrent PD-1 antibody-based long-term radiotherapy followed by 2 cycles SOX with PD-1 in patients with locally advanced adenocarcinoma of esophagogastric junction.
Status | Not yet recruiting |
Enrollment | 26 |
Est. completion date | December 2027 |
Est. primary completion date | January 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Histologically confirmed adenocarcinoma of esophagogastric junction, and Her-2 negative. 2. Clinically diagnosed stage T3+orN+M0, according to CT/MRI scan. 3. No prior anti-tumor treatment, including surgery, chemotherapy, radiotherapy, and targeted therapy. 4. Eastern Cooperative Oncology Group(ECOG) performance status(PS) 0-1. 5. At least one evaluable lesion in abdominal CT/MRI according to RESIST 1.1 is required. 6. Expected survival =6 months. 7. Adequate organ function, Hemoglobin =90g/L; White blood cells =3.0×109/L; neutrophil count =1.5×109/L; Platelets =100×109/L; Serum creatinine (SCr) = 1.5 times the upper limit of normal (ULN) or creatinine clearance rate = 50ml/min (Cockcroft-Gault formula); Total bilirubin (TBIL) = 1.5 times the ULN; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level = 2.5 times the ULN; Urine protein < 2+; if urine protein = 2+, 24-hour urine protein quantification shows that protein must be = 1 g. 8. Normal coagulation function, no active bleeding and thrombotic diseases: International Standardized Ratio INR=1.5×ULN; Partial thromboplastin time APTT=1.5×ULN; Prothrombin time PT=1.5ULN; 9. Previous use of anti-tumor Chinese medicines, proprietary Chinese medicines, and immunomodulators (such as thymosin, interleukin, etc.) must be = 2 weeks from the start of the study medication; 10. Female patients should not be pregnant or breast feeding. Male should contraception. 11. Able and willing to give informed consent to participate. 12. Those who are expected to have good compliance. Exclusion Criteria: 1. Existence of other active malignant tumors within 5 years or at the same time. 2. Already received chemotherapy, radiation therapy, targeted or immunotherapy. 3. Have any active autoimmune disease or history of autoimmune disease. 4. Patients with congenital or acquired immunodeficiency. 5. Use of immunosuppressive drugs within 14 days before the study start. 6. Administer live attenuated vaccines within 4 weeks before the study start. 7. Suffering from uncontrolled cardiac clinical symptoms or diseases, such as (1) NYHA II and above heart failure (2) unstable angina pectoris (3) myocardial infarction within 1 year (4) poorly controlled arrhythmia. 8. Patients with past and current interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, etc., and severely impaired lung function. 9. Suffering from active pulmonary tuberculosis. 10. Complicated severe infection within 4 weeks before the the study start, or unexplained fever >38.5°C during the screening period/before the study start. 11. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. 13. Allergic to any drug in this study. 14. Combined with other severe, acute and chronic diseases that may increase the risk of participating. 15.Participators who had been recruited by other clinical trial within three months. |
Country | Name | City | State |
---|---|---|---|
China | Peking University People's Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pathological Complete Responce (pCR) Rate | Proportion of patients with AEG who received neoadjuvant theray with radiation plus PD-1 antibody and SOX regimen and postoperative pathological examination shows pathological complete responce | Up to 6 months | |
Secondary | R0 Resection Rate | Proportion of patients with AEG who received surgery with pathological pathological examination proved microscopically margin-negative resection | Up to 6 months | |
Secondary | Progression Free Survival (PFS) | Disease Free Survival was defined as the time from the date of surgery to the date of the local recurrence, and/or distant disease, or tumor-related death. | Up to 3 years | |
Secondary | Adverse Events | For any adverse reactions, the researchers refer to the National Cancer Institute (NCI) standard of common toxicity (CTC) | Up to 6 months | |
Secondary | Surgery Morbidity | Surgical morbidity reported according to Clavien-Dindo classification | 30 days and 12-months after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05829213 -
A Modified Esophagogastric Reconstruction Method After Laparoscopic Proximal Gastrectomy
|
N/A | |
Recruiting |
NCT05729646 -
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
Not yet recruiting |
NCT04891900 -
TQB2450 (PD-L1 Inhibitor) Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
|
N/A | |
Active, not recruiting |
NCT01095120 -
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05970627 -
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT03734913 -
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06300879 -
A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique
|
N/A | |
Recruiting |
NCT05715931 -
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
|
Phase 2 | |
Not yet recruiting |
NCT06222944 -
Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
|
Phase 2 | |
Active, not recruiting |
NCT03302403 -
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
|
N/A | |
Recruiting |
NCT05872685 -
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
|
Phase 2 | |
Recruiting |
NCT04910789 -
Transhiatal/Transabdominal Approach Compare With Thoracoabdominal Approach for Siewert II Adenocarcinoma of Esophagogastric Junction
|
N/A | |
Recruiting |
NCT04813523 -
Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma
|
Phase 2 |